Delivery Order SPE2DB20D3103-SPE2DB23FM6D2
- Not listed
- This federal contract award, valued at $46,871.36, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Timolol 0.5% Gel-Solution 5ML. The contract is a Firm Fixed Price Delivery Order with a completion date of January 14, 2022. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which does business as Amerisourcebergen. Both companies are registered in the System for Award Management...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Timolol 0.5% Gel-Solution, a medication used to treat glaucoma. The $1,936.67 Firm Fixed Price Delivery Order contract has an ultimate completion date of October 19, 2022. AmerisourceBergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the...
- This federal contract award, issued by the Defense Logistics Agency (DLA), is for the delivery of Timolol 0.5% gel-solution medical products to support military healthcare programs. The $3,005.89 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a Delivery Order valued at $6,085.20 for the supply of Timolol 0.5% gel-solution. The contract was awarded by the Defense Logistics Agency (DLA), a Defense agency, and has no set-aside designation. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026, which serves as the primary vehicle for the company to...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, covers the delivery of Timolol 0.5% Gel-Solution (5ml) to support government healthcare programs. The $14,197.90 delivery order was issued by the Defense Logistics Agency (DLA) and has a January 2022 completion date. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a wide range of...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is a Delivery Order valued at $2,194.34 for the supply of Timolol 0.5% GFS Gel-Solution with a completion date of February 9, 2024. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which serves as the primary vehicle for...
- This federal contract award to Amerisourcebergen Drug Corp (a subsidiary of Cencora, Inc.) is a Delivery Order valued at $15,221.30 for the supply of Timolol 0.25% Gel-Solution 5ML. The contract, awarded by the Defense Logistics Agency (DLA), has an ultimate completion date of October 20, 2021 and utilizes a Firm Fixed Price pricing type. This award is not designated as a set-aside contract. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with...
- This federal contract award is a delivery order placed with Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) for the supply of Timolol 0.5% Gel-Solution, a topical eye medication, with a ceiling value of $5,624.58. The delivery order has an ultimate completion date of April 3, 2024 and is a firm fixed-price contract. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant $999,999,999...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,871.28 firm fixed-price delivery order is for the supply of Timolol 0.5% gel-solution, a medication used to treat glaucoma. The award is not associated with a set-aside program and was issued as an individual delivery order under Amerisourcebergen's $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a pharmaceutical distribution company owned by Cencora, Inc. The award, valued at $1,893.42, is for the delivery of 5 mL bottles of Timolol 0.5% Gel-Solution, a medication used to treat glaucoma and other eye conditions. The contract has an ultimate completion date of December 8, 2023 and is structured as a Firm Fixed Price Delivery Order, with no set-aside...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB23FM6D2Delivery Order
This federal contract award, valued at $5,173.74, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Timolol 0.5% gel-solution (5ml). The contract is a firm fixed-price Delivery Order that runs through March 2, 2023. Amerisourcebergen Drug Corp is a subsidiary of the parent company, Cencora, Inc., which also holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract award does not have a set-aside designation, indicating it was competed openly. This delivery order supports the procurement of essential medications by the DLA to meet the healthcare needs of military personnel, veterans, and other federal beneficiaries.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.2k | 3/1/23 |